AS Healthcare Advanced Synthesis (HAS), backed by 65 Equity Partners, has acquired a stake in Cerbios-Pharma, a global manufacturer of chemical and biological active pharmaceutical ingredients (APIs), including those for antibody-drug conjugates (ADCs).
Financial details of the transaction were not disclosed.
Following the deal, 65 Equity Partners will hold around 40% of the combined entity, with the Braglia family maintaining majority ownership.
The merger of HAS and Cerbios strengthens their position in the Contract Development and Manufacturing Organization (CDMO) sector, combining expertise in chemical and biological production, and expanding their service offerings for the pharmaceutical industry. Both companies are based in Switzerland and serve international markets.
The investment by 65 Equity Partners supports its focus on growing family-owned businesses with strong technical capabilities and growth potential.
The deal positions the new group for further expansion, leveraging increasing demand for complex therapies and innovation in various therapeutic areas, including oncology and rare diseases.
HAS was advised by Rothschild & Co (financial), Bär & Karrer (legal), and EY (accounting/tax).
65 Equity Partners was advised by UBS AG (financial), Ropes & Gray and Walder Wyss (legal), EY (accounting/tax), Pharmacloud and Guidance Pharm (commercial), JensonR+ (regulatory), and Orbsen (technical).
